% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vonTresckow:301266,
      author       = {B. von Tresckow$^*$ and P. Abrisqueta and I. Zamanillo and
                      Á. S. Pareja and Y. Kuang and J. Uyei and M. Shah and L.
                      Walsh and E. Thorley and K. Cantos and E. Rashidi and C.
                      Hampp and J. J. Jalbert and A. N. Archambault and Y. Xu and
                      S. Aggarwal and S. Ambati and H. Mohamed and Q. Ma and A.
                      Jiménez-Ubieto},
      title        = {{P}rognostic {F}actors and {E}ffect {M}odifiers in
                      {P}atients {W}ith {R}elapse or {R}efractory {D}iffuse
                      {L}arge {B}-{C}ell {L}ymphoma {A}fter {T}wo {L}ines of
                      {T}herapy: {A} {S}ystematic {L}iterature and {E}xpert
                      {C}linical {R}eview.},
      journal      = {European journal of haematology},
      volume       = {115},
      number       = {2},
      issn         = {0902-4441},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2025-00951},
      pages        = {104-116},
      year         = {2025},
      note         = {2025 Aug;115(2):104-116},
      abstract     = {The objective of this systematic literature review (SLR)
                      combined with expert clinical review was to identify and
                      rank prognostic factors and effect measure modifiers (EMMs)
                      systematically and comprehensively in patients with relapsed
                      or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
                      who initiate treatment after ≥ 2 prior lines of therapy
                      (LoTs; 3L+ R/R DLBCL).We performed an SLR of studies
                      published between 2016 and 2021 and extracted study
                      characteristics, prognostic factors, and EMMs. This was
                      followed by clinical review and ranking of findings by
                      subject matter experts using questionnaires, follow-up
                      interviews, and quantitative ranking.Across 46 included
                      studies, the SLR identified 36 prognostic factors
                      significantly associated with ≥ 1 clinical outcome. Based
                      on subject matter expert ranking of the SLR-derived list,
                      the five most important prognostic variables in descending
                      order are: early chemo-immunotherapy failure, Eastern
                      Cooperative Oncology Group performance status, refractory to
                      last LoT, number of prior LoTs, and double- or triple-hit
                      lymphoma.This SLR and expert clinical review is the first to
                      provide a comprehensive assessment of prognostic factors for
                      3L+ R/R DLBCL. No statistically significant EMMs were
                      identified. This robust multi-method approach can assist in
                      selecting prognostic variables for comparative analyses
                      between real-world studies and clinical trials.},
      subtyp        = {Review Article},
      keywords     = {comparative effectiveness research (Other) / diffuse large
                      B‐cell lymphoma (Other) / systematic review (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40344463},
      doi          = {10.1111/ejh.14423},
      url          = {https://inrepo02.dkfz.de/record/301266},
}